Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

Clinical trial NCT07314216 · RECRUITING

Trial details

NCT number: NCT07314216
Sponsor: Hunan Cancer Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC (Non-small Cell Lung Carcinoma)Stage III EGFR Uncommon Mutations

Start date: 2026-06-22
Primary completion: 2030-12-31
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.